戻る
「早戻しボタン」を押すと検索画面に戻ります。 [閉じる]

コーパス検索結果 (１語後でソート)

通し番号をクリックするとPubMedの該当ページを表示します
1                           The NH(2)-terminal somatomedin B (SMB) domain (residues 1-44) of human vitr
2                 The N-terminal cysteine-rich somatomedin B (SMB) domain (residues 1-44) of the human
3 ocalized to the NH(2)-terminal cysteine-rich somatomedin B (SMB) domain (residues 1-44).
4       The primary sequence of the N-terminal somatomedin B (SMB) domain of native vitronectin contain
5 n activator inhibitor 1 (PAI-1) binds to the somatomedin B (SMB) domain of vitronectin (VN), a domain
6  uPAR only bound to fragments containing the somatomedin B (SMB) domain, and monoclonal antibodies (m
7 ino acids from human plasma vitronectin, the somatomedin B (SMB) domain, has been determined by two-d
8 lasma glycoprotein vitronectin, known as the somatomedin B (SMB) domain, mediates the interaction bet
9  been attributed primarily to binding of the somatomedin B (SMB) domain, which comprises the N-termin
10 f vitronectin with respect to the N-terminal somatomedin B (SMB) domain.
11  within residues 12-30 in the amino-terminal somatomedin B (SMB) domain.
12 omic analysis identified 2 proteins, SBSPON (somatomedin B and thrombospondin type 1 domain-containin
13                     In contrast to the PAI-1-somatomedin B binding, the second interaction had almost
14 ndary site, a vitronectin mutant lacking the somatomedin B domain (rDeltasBVN) was engineered.
15                                          The somatomedin B domain of vitronectin (SMBD) did not affec
16 e for PAI-1 is located within the N-terminal somatomedin B domain of vitronectin; however, several st
17 he same site in VN (i.e., the amino-terminal somatomedin B domain; SMB), and that PAI-1 competes with
18 ately 100-fold higher than that of the PAI-1-somatomedin B interaction.
19 ein', contains domains that have homology to somatomedin B, heparin-binding proteins, mucins and haem
20                     The opposite face of the somatomedin B-like domain interacts with the catalytic p
21  the PDE domain is flanked by two N-terminal somatomedin B-like domains and a C-terminal inactive nuc
22 ent-exposed surface of the N-terminal tandem somatomedin B-like domains in binding to platelet integr
23 the ENPP1 enzyme that is mediated by its two somatomedin-B-like domains.
24                                              Somatomedin C/insulin-like growth factor-I (IGF-I) is re
25                            Thus the original somatomedin hypothesis has undergone further modificatio
26                                          The somatomedin hypothesis proposed that insulin-like growth